Chad Cook, a lawyer in our firm’s Mass Torts Section, has been selected to help direct litigation related to femur fractures caused by the osteoporosis medication Fosamax®. Chad is one of 11 lawyers appointed by U.S. District Judge Garrett E. Brown, Jr., the MDL judge, to oversee the consolidated litigation as part of the Plaintiffs Steering Committee (PSC). The litigation, which involves hundreds of cases against Merck Sharp & Dohme, Corp., which manufactures Fosamax®, is consolidated by Judge Brown in the District of New Jersey.
It’s quite an honor for Chad to be selected to serve on the Fosamax Femur Fracture PSC. He will be working with a group of very good lawyers representing the victims who have suffered injuries due to their taking Fosamax. As you may already know, Fosamax is a type of medication known as a bisphosphonate, prescribed for the treatment of bone loss and osteoporosis. The FDA reviewed data from an ongoing safety review of oral bisphosphonates to determine if use of the drug was related to an increased risk of thigh fractures, specifically low-energy femoral shaft and subtrochanteric fractures. In October of 2010 the FDA required all manufacturers of bisphosphonates to include in the warning section of their label a description of low-energy femoral shaft and subtrochanteric fractures that are associated with the use of drugs in this class.
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.